Cook et al. [199] administered the GRP78-targeting morpholino to abrogate the resistance to tamoxifen in the MCF-7/LCC1 tumor xenografts; in the morpholino-injected mice, the researchers found the elevated serum levels of monocyte chemotactic protein 1 along with the reduced CD47 expression and augmented macrophage infiltration in the GRP78-depleted tumor areas. The gene discussed is CCL2; the disease is neoplasm.